Daxor's Blood Volume Analyzer (BVA-100®) To Be Used As a Key Metric in Study of “Long Hauler” COVID-19 PatientsGlobeNewsWire • 05/25/22
Daxor Corporation to Present at the H.C. Wainwright & Company Global Investment ConferenceGlobeNewsWire • 05/12/22
Daxor Corporation to Participate in the Maxim Group 2022 Virtual Growth ConferenceGlobeNewsWire • 03/23/22
Study Demonstrates Importance and Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in the Assessment of Heart FailureGlobeNewsWire • 02/17/22
Daxor Corporation to Commence Trading on The Nasdaq Capital Market On February 2, 2022GlobeNewsWire • 01/20/22
Daxor Corporation to Present at the H.C. Wainwright BioConnect 2022 Virtual ConferenceGlobeNewsWire • 01/06/22
DAXOR AWARDED NEW PATENT FOR BLOOD VOLUME GUIDANCE TECHNOLOGY TO IMPROVE TREATMENT AND OUTCOMESGlobeNewsWire • 01/04/22
Daxor Corporation Presents New Data Validating the Benefit of the BVA-100® Blood Test for Heart Failure Patients at Key Scientific Society MeetingGlobeNewsWire • 09/14/21
Daxor Corporation to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual ConferenceGlobeNewsWire • 09/07/21
Daxor Corporation Reports a 26.5 Percent Rise in Diagnostic Sales Revenue in Form N-CSR Filing for the Six Months Ended June 30, 2021GlobeNewsWire • 08/30/21
Daxor's Blood Volume (BVA-100®) Diagnostic Demonstrates Clinical Utility In Critically-Ill COVID-19 Patients In Newly Published Data in Journal Critical CareGlobeNewsWire • 08/04/21
DAXOR CORPORATION ANNOUNCES NON-GOVERNMENT DISTRIBUTION AGREEMENT WITH CONCORDANCE® HEALTHCARE SOLUTIONSGlobeNewsWire • 07/22/21
American College of Cardiology (ACC) Features Expert Analysis on the Importance of Addressing Anemia With Blood Volume Analysis in Heart Failure PatientsGlobeNewsWire • 07/13/21
Daxor Corporation to Present at the Summer Solstice - Best Ideas from the Buy Side Conference on June 2, 2021GlobeNewsWire • 05/28/21
Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.GlobeNewsWire • 05/13/21
Newly Published Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in the Assessment of Postural Tachycardia Syndrome (POTS)GlobeNewsWire • 04/29/21
Daxor to Participate in the Maxim Group 2021 Emerging Growth Virtual ConferenceGlobeNewsWire • 03/16/21
DAXOR CORPORATION ANNOUNCES NOVEL FLUORESCENT TRACER AND PHASE-TWO US AIR FORCE CONTRACT AWARD OF $750,000 FOR POINT-OF-CARE OPTICAL BLOOD VOLUME ANALYZERGlobeNewsWire • 03/15/21
Daxor Corporation Announces $0.48 Per Share NAV Increase and Files Annual Report for Fiscal 2020GlobeNewsWire • 02/26/21
DAXOR CORPORATION RECEIVES ISO 13485 QUALITY MANAGEMENT SYSTEM CERTIFICATION FOR THE BLOOD VOLUME ANALYZER (BVA-100®)GlobeNewsWire • 02/19/21
DAXOR CORPORATION AWARDED GRANT FROM THE CENTER FOR ADVANCING POINT OF CARE TECHNOLOGIES (CAPCAT) TO DEVELOP A POINT-OF-CARE BLOOD VOLUME ANALYZERGlobeNewsWire • 02/05/21